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Abstract
Background: During pregnancy, the mammary glands from Id2 mutant animals are deficient in
lobulo-alveolar development. This failure of development is believed to be due to a proliferation
defect.
Methods:  We have asked whether functional Id2  expression is necessary for Wnt induced
mammary hyperplasia, side branching, and cancer, by generating mice expressing a Wnt1 transgene
in an Id2 mutant background.
Results: We show in this work that forced expression of Wnt1 in the mammary gland is capable
of overcoming the block to proliferation caused by the absence of Id2. We also show that Wnt1
expression is able to cause mammary tumors in an Id2 mutant background.
Conclusions: We conclude that functional Id2 expression is not required for Wnt1 to induce
mammary hyperplasia and mammary tumors.
Background
Basic helix-loop-helix (bHLH) transcription factors such
as MyoD, E12, and E47 are key regulators of gene expres-
sion and control many differentiation events during
development [1-3]. These transcription factors bind E-box
or E-box-like sequences as homo-or heterodimers, and
control the transcription of target genes containing these
sequences in their promoters. The HLH domains dimerize
with each other, whereas the basic domains bind to DNA.
The Id (Inhibitor of DNA binding) proteins are HLH pro-
teins that lack a basic domain. Id proteins act as dominant
inhibitors of bHLH transcription factors by blocking their
ability to bind to DNA and activate gene transcription
[2,3]. Since the bHLH proteins regulate cell-type specific
gene expression during cell commitment and differentia-
tion, the formation of inactive heterodimers of bHLH pro-
teins with Id proteins inhibits the commitment and
differentiation the bHLH proteins promote.
There are 4 mammalian Id genes, which show differences
in their patterns of expression and function [2,3]. One of
them, Id2, is expressed in glandular and ductal epithelium
of the mouse mammary gland and has also been impli-
cated in its development. Mammary glands of female
mice that are homozygous mutant for Id2 have impaired
lobulo-alveolar development [4]. In several tissues,
including colon tumors induced by activation of the Wnt
pathway, the expression of Id2 is regulated by Wnt-β cat-
enin signaling [5,6]. It has been proposed that Wnt sign-
aling may inhibit differentiation and promote the
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maintenance of a proliferative state by increasing Id2
expression, thereby leading to cancer. We have asked
therefore whether functional Id2 expression is necessary
for Wnt induced mammary hyperplasia, side branching
and cancer, by generating mice expressing a Wnt1 trans-
gene in an Id2 mutant background.
Methods
We used heterozygous Id2 males and females on a 129/Sv
background. Id2 genotyping was done by PCR (95C, 5
min; 62C, 1 min, 72C, 1 min, 95C,1 min, 30 cycles; 62C,
1 min, 72C, 5 min) using primers Id2-S (5'-tctgagcttatgtc-
gaatgatagc-3'), Id-2AS (5'-cgtgttctcctggtgaaatggctg-3'), and
neo 1 (5'-tcgtgctttacggtatcgccgctc-3").
Hemizygous transgenic MMTV-Wnt1 males on a mixed
FVB/BL6/SJL background were obtained from Yi Li in the
H.Varmus laboratory. Genotyping was done by PCR
(94C, 4 min; 94C, 45 sec, 55C, 30 sec, 72C, 60 sec, 30
cycles; 72C, 10 min) using Wnt1 (5'-gaacttgcttctcttctcat-
agcc-3') and SV40 (5'-ccacacaggcatagagtgtctgc-3') primers
that produce a 350 bp product in transgenic mice.
Carmine staining
Five mammary glands per mouse were removed and fat
and muscle were dissected away. The glands were flat-
tened between two slides and flooded with Carnoy's fixa-
tive (3:1 95% ethanol to glacial acetic acid) and fixed
overnight. They were then de-fatted in 3 changes of ace-
tone, rehydrated, stained overnight in 0.2% carmine and
0.5%KSO4, dehydrated, cleared in xylene, and mounted
in Permount.
Results
We used mice carrying a transgene in which Wnt1 is under
the control of the promoter of the Mouse Mammary
Tumor Virus (MMTV-Wnt1 Tg) [7] and we crossed these
to Id2 loss of function mutant mice [4,8]. Crosses were set
up to avoid reliance on Id2 -/- or Wnt1 transgenic moth-
ers, as these animals cannot feed their young [4,7]. Id2 +/
- females were crossed with MMTV-Wnt1 hemizygous
transgenic males, producing 7 MMTV-Wnt1 Tg; Id2+/-
males (Figure 1). These males were then crossed with Id2
+/- females to produce the experimental and control
classes of virgin female mice: MMTV-Wnt1 Tg; Id2  -/-,
MMTV-Wnt1 Tg ; Id2 +/-, and MMTV-Wnt1 Tg; Id2, as well
as smaller numbers of animals in Id2 -/-; Id2 +/-; and WT
classes. (Figure 1)
The subject animals were kept in mixed groups in auto-
claved cages because Id2 -/- mice have an immunologic
defect. Even with this care, 50% die before maturity [8].
Id2 -/- mice were born in sub-Mendelian ratios, they were
smaller than litter-mates, and several died of unknown
causes.
We examined the morphology of the mammary gland. At
3, 4.5, and 6 months the ductal branching patterns in nor-
mal mammary glands of 24 virgin mice from all six classes
were examined in carmine stained whole mounts (Figure
2). As has been previously observed by others, the MMTV-
Wnt1 Tg female glands had excessive ductal side branch-
ing compared to those of WT females [7] while Id2 +/- and
Id2 -/- females glands were similar to those of WT females
[4]. Glands from MMTV-Wnt1 Tg ; Id2 +/- and MMTV-
Wnt1 Tg ; Id2 -/- mice had branching patterns resembling
those of MMTV-Wnt1 Tg females at 3 months (Figure 2).
At six months the three classes of transgenic mammary
glands had very extensive, dense hyperplasia and side
branching resembling that of pregnant wild type mice,
while the six month virgin Id2+/- and Id2-/- glands had no
additional branching and the six month virgin WT glands
had moderate additional branching. Therefore, it appears
that forced expression of Wnt1 in virgin mammary glands
can overcome the absence of Id2 and lead to a highly
branched ductal tree resembling the tree achieved nor-
mally during pregnancy.
In parallel, we examined tumor incidence in the animals.
We excluded MMTV-Wnt1 Tg ; Id2 -/- females that died
without developing tumors before 34 weeks, our end-
point, leaving only 8 animals in this group. Mice were
examined and palpated weekly for mammary tumors. The
smallest tumors detected using this method were 0.5 cm
in diameter, but could be as large as 2 cm. The MMTV-
The Wnt1 transgene was crossed into an Id2 -/- background  in order to produce cohorts of WT, Id2 +/-, and Id2 -/-  females with and without the Wnt1 transgene Figure 1
The Wnt1 transgene was crossed into an Id2 -/- background 
in order to produce cohorts of WT, Id2 +/-, and Id2 -/- 
females with and without the Wnt1 transgene. The scheme 
was designed so that mothers could feed their own young 
and so that all cohorts being compared would share a com-
mon background.
￿ MMTV-Wnt1; Id2+/+ X ￿Id2+/-
￿
￿ MMTV-Wnt1; Id2+/- X ￿Id2+/-
￿
￿ MMTV-Wnt1; Id2-/-
￿ MMTV-Wnt1; Id2+/-
￿ MMTV-Wnt1; Id2+/+
plus same Id2 combinations without MMTV-Wnt1 transgeneBMC Cancer 2004, 4:91 http://www.biomedcentral.com/1471-2407/4/91
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Wnt1 Tg ; Id2 +/+ and MMTV-Wnt1 Tg ; Id2 +/- cohorts
consisted of 21 and 23 females respectively. All three
cohorts showed a similar rate of tumorigenesis (Figure 3).
We concluded that Wnt1 is epistatic to Id2 in tumorigen-
esis, just as it is in promoting hyperplasia and side branch-
ing of the mammary gland (Figure 2).
Discussion
The lack of Id2, a Wnt target, has severe consequences for
mouse mammary gland development. During pregnancy,
the Id2 mammary gland is deficient in lobulo-alveolar
development. This failure of development is believed to
be due to a proliferation failure rather than precocious dif-
ferentiation of the mammary epithelia [4]. We show in
this work that forced expression of Wnt1 in the mammary
gland is capable of overcoming this block to proliferation.
Although many targets of the Wnt pathway have been
identified (see http://www.stanford.edu/~rnusse/path
ways/targets.html), the mechanism through which hyper-
plasia and side branching is promoted by Wnt1
Carmine stained mammary gland whole mounts were made from virgin females Figure 2
Carmine stained mammary gland whole mounts were made from virgin females. Top row, left to right: normal mammary gland 
development was observed in wild type (13 weeks), Id2 +/- (26 weeks), and Id2-/- (26 weeks) animals. Bottom row, left to 
right: Wnt1 induced hyperplasia and side branching were forced when the MMTV-Wnt1 transgene was present in wild type, 
Id2+/-, and Id2 -/- animals (all 19 weeks). Branching patterns are representative of a consistent phenotype observed in all mice 
and in both tumor-free glands and in glandular tissue associated with tumors in the MMTV-Wnt1 mice.BMC Cancer 2004, 4:91 http://www.biomedcentral.com/1471-2407/4/91
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expression in the virgin mammary gland is unknown. Our
results demonstrate that Wnt1 is not operating solely
through Id2 or that it is not operating through Id2 at all.
Another known Wnt target with a similar loss of function
phenotype is Cyclin D1 [9], a protein whose expression
promotes advancement through the cell cycle and whose
over expression results in hyperplasia and tumors in the
mammary gland [10]. However, when Wnt1 is expressed
in Cyclin D1 -/- mice, only a slight reduction in tumori-
genesis is observed [11], suggesting that the Wnt1 path-
way also does not operate primarily through Cyclin D1.
Furthermore, over expression of Cyclin D1 did not pro-
mote lobulo-alveolar development in Id2-/- mice [12], a
result that is in contrast to the dense side branching of the
Wnt1 Id2-/- phenotype, suggesting that Wnt1 signaling is
independent of both Cyclin D1 and Id2 in the mammary
gland.
Conclusions
By showing that forced expression of Wnt1 in the mam-
mary gland is capable of overcoming the block to prolifer-
ation caused by the absence of Id2, we conclude that
functional Id2 expression is not required for Wnt1 to
induce mammary hyperplasia and mammary tumors.
Three cohorts of mice, MMTV-Wnt1 Tg (n = 21), MMTV-Wnt1 Tg; Id2 +/- (n = 23), and MMTV-Wnt1 Tg; Id2 -/- (n = 8) were  examined weekly by visual examination and palpation Figure 3
Three cohorts of mice, MMTV-Wnt1 Tg (n = 21), MMTV-Wnt1 Tg; Id2 +/- (n = 23), and MMTV-Wnt1 Tg; Id2 -/- (n = 8) were 
examined weekly by visual examination and palpation. No differences in tumor incidence were observed. MMTV-Wnt1 Tg : 
square; MMTV-Wnt1 Tg; Id2 +/- : diamond; MMTV-Wnt1 Tg; Id2 -/-: triangle.
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